- New, Novel Lipid-Lowering Agents for Reducing Cardiovascular Risk: Beyond Statins
-
Kyuho Kim, Henry N. Ginsberg, Sung Hee Choi
-
Diabetes Metab J. 2022;46(5):817-818. Published online September 19, 2022
-
DOI: https://doi.org/10.4093/dmj.2022.0295
-
Corrects: Diabetes Metab J 2022;46(4):517
-
2,898
View
-
167
Download
-
6
Web of Science
-
6
Crossref
-
 PDF PubReader  ePub
-
Citations
Citations to this article as recorded by  - Addressing residual risk beyond statin therapy: New targets in the management of dyslipidaemias–A report from the European Society of Cardiology Cardiovascular Round Table
François Mach, Frank L.J. Visseren, Nilo B. Cater, Nejoua Salhi, Jarkko Soronen, Kausik K. Ray, Victoria Delgado, J. Wouter Jukema, Ulrich Laufs, Jose-Luis Zamorano, Emilio Ros, Jogchum Plat, Akos Gabor Gesztes, Lale Tokgozoglu, Chris Packard, Peter Libby
Journal of Clinical Lipidology.2024; 18(5): e685. CrossRef - Engineered exosomes as a prospective therapy for diabetic foot ulcers
Lifei Guo, Dan Xiao, Helin Xing, Guodong Yang, Xuekang Yang
Burns & Trauma.2024;[Epub] CrossRef - Lipidomic profiling in patients with familial hypercholesterolemia: Abnormalities in glycerolipids and oxysterols
Shiva Ganjali, Vladimiro Cardenia, Ambra Bonciolini, Raul D. Santos, Khalid Al-Rasadi, Amirhossein Sahebkar
Clinical Biochemistry.2024; 131-132: 110812. CrossRef - Olezarsen and Plozasiran in Dyslipidemia Management: A Narrative Review of Clinical Trials
Gbolahan Olatunji, Ikponmwosa Jude Ogieuhi, Emmanuel Kokori, Ajekiigbe Victor Oluwatomiwa, Oluwafemi Isaiah Ajimotokan, God-dowell O. Odukudu, Samuel Owolabi, Sopuruchukwu Anyacho, Chijindu Nnaemeka Nwakama, Adetola Emmanuel Babalola, Franklin Andibanbang
High Blood Pressure & Cardiovascular Prevention.2024; 31(6): 567. CrossRef - The Effect of Statin Therapy on Bone Metabolism Markers and Mineral Density: Aa GRADE-Assessed Systematic Review and Dose-Response Meta-Analysis of Randomized Controlled Trials
Seyyed Mostafa Arabi, Mahla Chambari, Leila Sadat Bahrami, Ali Jafari, Hossein Bahari, Željko Reiner, Amirhossein Sahebkar
Advanced Pharmaceutical Bulletin.2024; 14(3): 591. CrossRef - Remnant Cholesterol, a Valuable Biomarker for Assessing Arteriosclerosis and Cardiovascular Risk: A Systematic Review
Xiang Chen, Li-Hua Li
Cureus.2023;[Epub] CrossRef
- Drug/Regimen
- New, Novel Lipid-Lowering Agents for Reducing Cardiovascular Risk: Beyond Statins
-
Kyuho Kim, Henry N. Ginsberg, Sung Hee Choi
-
Diabetes Metab J. 2022;46(4):517-532. Published online July 27, 2022
-
DOI: https://doi.org/10.4093/dmj.2022.0198
-
Correction in: Diabetes Metab J 2022;46(5):817
-
13,540
View
-
987
Download
-
38
Web of Science
-
39
Crossref
-
 Abstract
PDFPubReader ePub
- Statins are the cornerstone of the prevention and treatment of atherosclerotic cardiovascular disease (ASCVD). However, even under optimal statin therapy, a significant residual ASCVD risk remains. Therefore, there has been an unmet clinical need for novel lipid-lowering agents that can target low-density lipoprotein cholesterol (LDL-C) and other atherogenic particles. During the past decade, several drugs have been developed for the treatment of dyslipidemia. Inclisiran, a small interfering RNA that targets proprotein convertase subtilisin/kexin type 9 (PCSK9), shows comparable effects to that of PCSK9 monoclonal antibodies. Bempedoic acid, an ATP citrate lyase inhibitor, is a valuable treatment option for the patients with statin intolerance. Pemafibrate, the first selective peroxisome proliferator-activated receptor alpha modulator, showed a favorable benefit-risk balance in phase 2 trial, but the large clinical phase 3 trial (PROMINENT) was recently stopped for futility based on a late interim analysis. High dose icosapent ethyl, a modified eicosapentaenoic acid preparation, shows cardiovascular benefits. Evinacumab, an angiopoietin-like 3 (ANGPTL3) monoclonal antibody, reduces plasma LDL-C levels in patients with refractory hypercholesterolemia. Novel antisense oligonucleotides targeting apolipoprotein C3 (apoC3), ANGPTL3, and lipoprotein(a) have significantly attenuated the levels of their target molecules with beneficial effects on associated dyslipidemias. Apolipoprotein A1 (apoA1) is considered as a potential treatment to exploit the athero-protective effects of high-density lipoprotein cholesterol (HDL-C), but solid clinical evidence is necessary. In this review, we discuss the mode of action and clinical outcomes of these novel lipid-lowering agents beyond statins.
-
Citations
Citations to this article as recorded by - The role of adherence in patients with chronic diseases
Michel Burnier
European Journal of Internal Medicine.2024; 119: 1. CrossRef - Genetic insights into repurposing statins for hyperthyroidism prevention: a drug-target Mendelian randomization study
Anqi Huang, Xinyi Wu, Jiaqi Lin, Chiju Wei, Wencan Xu
Frontiers in Endocrinology.2024;[Epub] CrossRef - Targeting host-specific metabolic pathways—opportunities and challenges for anti-infective therapy
Monika I. Konaklieva, Balbina J. Plotkin
Frontiers in Molecular Biosciences.2024;[Epub] CrossRef - Neutrophil Extracellular Traps (NETs) and Atherosclerosis: Does Hypolipidemic Treatment Have an Effect?
Petros Adamidis, Despoina Pantazi, Iraklis Moschonas, Evangelos Liberopoulos, Alexandros Tselepis
Journal of Cardiovascular Development and Disease.2024; 11(3): 72. CrossRef - Modulating effects of crocin on lipids and lipoproteins: Mechanisms and potential benefits
Habib Yaribeygi, Mina Maleki, Farin Rashid-Farrokhi, Payman Raise Abdullahi, Mohammad Amin Hemmati, Tannaz Jamialahmadi, Amirhossein Sahebkar
Heliyon.2024; 10(7): e28837. CrossRef - Assessing the Benefits of Lifestyle Influences on Cardiovascu-lar Health After Acute Coronary Syndrome
Marius Rus, Claudia Elena Stanis, Paula Marian, Lilliana Oana Pobirci, Loredana Ioana Banszki, Veronica Huplea, Gheorghe Adrian Osiceanu, Bianca-Maria Pop, Gabriela Dogaru, Felicia Liana Andronie-Cioara
Balneo and PRM Research Journal.2024; 15(Vol.15, no): 660. CrossRef - Comprehensive mendelian randomization analysis of plasma proteomics to identify new therapeutic targets for the treatment of coronary heart disease and myocardial infarction
Ziyi Sun, Zhangjun Yun, Jianguo Lin, Xiaoning Sun, Qingqing Wang, Jinlong Duan, Cheng Li, Xiaoxiao Zhang, Siyu Xu, Zeqi Wang, Xingjiang Xiong, Kuiwu Yao
Journal of Translational Medicine.2024;[Epub] CrossRef - Hypercholesterolemia: A literature review on management using tafolecimab – a novel member of PCSK9 monoclonal antibodies
Zaheer Qureshi, Mikail Khanzada, Adnan Safi, Eeshal Fatima, Faryal Altaf, Timothy J. Vittorio
Annals of Medicine & Surgery.2024;[Epub] CrossRef - Therapeutic approach in the treatment of dyslipidemia: Novelties and challenges
Katarina Lalić, Nataša Rajković, Ljiljana Popović, Sandra Singh-Lukač, Iva Rasulić, Ana Petakov, Milica Krstić, Marija Mitrović
Galenika Medical Journal.2024; 3(9): 31. CrossRef - Lipid Variability Induces Endothelial Dysfunction by Increasing Inflammation and Oxidative Stress
Marie Rhee, Joonyub Lee, Eun Young Lee, Kun-Ho Yoon, Seung-Hwan Lee
Endocrinology and Metabolism.2024; 39(3): 511. CrossRef - Exploring the Perceptions and Behaviours of UK Prescribers Concerning Novel Lipid-Lowering Agent Prescriptions: A Qualitative Study
Sarah Baig, Shahrauz Mughal, Yousuf Murad, Mandeep Virdee, Zahraa Jalal
Pharmacy.2024; 12(4): 104. CrossRef - Need of education and training of healthcare professionals on the PCSK9 inhibitors in cardiovascular disease
Jan Schjøtt, Kristine Heitmann
European Journal of Cardiovascular Nursing.2024;[Epub] CrossRef - CXCL9, IL2RB, and SPP1, potential diagnostic biomarkers in the co-morbidity pattern of atherosclerosis and non-alcoholic steatohepatitis
Xize Wu, Changbin Yuan, Jiaxiang Pan, Yi Zhou, Xue Pan, Jian Kang, Lihong Ren, Lihong Gong, Yue Li
Scientific Reports.2024;[Epub] CrossRef - Lessons from PROMINENT and prospects for pemafibrate
Jean-Charles Fruchart, Jamila Fruchart-Najib, Shizuya Yamashita, Peter Libby, Koutaro Yokote, Tatsuhiko Kodama, Yohei Tomita, Paul M. Ridker, Michel P. Hermans, Alberto Zambon
Cardiovascular Diabetology.2024;[Epub] CrossRef - A novel lncRNA GM47544 modulates triglyceride metabolism by inducing ubiquitination-dependent protein degradation of APOC3
Qianqian Xiao, Luyun Wang, Jing Wang, Man Wang, Dao Wen Wang, Hu Ding
Molecular Metabolism.2024; 88: 102011. CrossRef - Advances in pharmacotherapy of dyslipidemia
Harshitha Chinta
National Journal of Pharmacology and Therapeutics.2024; 2(2): 68. CrossRef - ANGPTL3 as a target for treating lipid disorders in type 2 diabetes patients
Jingfei Chen, Qin Luo, Yanfeng Yi, Jiangang Wang, Pengfei Chen, Fei Luo, Zhenfei Fang
Lipids in Health and Disease.2024;[Epub] CrossRef - Assessing the effects of HMGCR, LPL, and PCSK9 inhibition on sleep apnea: Mendelian randomization analysis of drug targets
Wei Tan, Xiujuan Deng, Xiaoning Tan, Guangbo Tan
Medicine.2024; 103(43): e40194. CrossRef - Causal association between remnant cholesterol level and risk of cardiovascular diseases: a bidirectional two sample mendelian randomization study
Lei Zhong, Bo Xie, Hai-Li Wang, Xiao-Wei Ji
Scientific Reports.2024;[Epub] CrossRef - A bibliometric analysis of immunotherapy for atherosclerosis: trends and hotspots prediction
Jing-Hui Wang, Guan-Rui Pan, Long Jiang
Frontiers in Immunology.2024;[Epub] CrossRef - Liver cancer cells as the model for developing liver-targeted RNAi therapeutics
Beibei Hou, Linhui Qin, Linfeng Huang
Biochemical and Biophysical Research Communications.2023; 644: 85. CrossRef - Insights into Causal Cardiovascular Risk Factors from Mendelian Randomization
C. M. Schooling, J. V. Zhao
Current Cardiology Reports.2023; 25(2): 67. CrossRef - Secoisolariciresinol diglucoside and anethole ameliorate lipid abnormalities, oxidative injury, hypercholesterolemia, heart, and liver conditions
Sana Noreen, Habib‐ur Rehman, Tabussam Tufail, Huma Badar Ul Ain, Chinaza Godswill Awuchi
Food Science & Nutrition.2023; 11(6): 2620. CrossRef - Colesterol remanente, riesgo vascular y prevención de la arteriosclerosis
Xavier Pintó, Marta Fanlo, Virginia Esteve, Jesús Millán, Agustín Blanco, Mariano Blasco, José Luís Díaz Díaz, Ángel Díaz Rodríguez, Alipio Mangas, Vicente Pascual, Juan Pedro Botet, Pablo Pérez Martínez
Clínica e Investigación en Arteriosclerosis.2023; 35(4): 206. CrossRef - Evolving Management of Low‐Density Lipoprotein Cholesterol: A Personalized Approach to Preventing Atherosclerotic Cardiovascular Disease Across the Risk Continuum
Michael J. Wilkinson, Norman E. Lepor, Erin D. Michos
Journal of the American Heart Association.2023;[Epub] CrossRef - The cell origins of foam cell and lipid metabolism regulated by mechanical stress in atherosclerosis
Zhi Ouyang, Jian Zhong, Junyi Shen, Ye Zeng
Frontiers in Physiology.2023;[Epub] CrossRef - Triglyceride-Rich Lipoprotein Metabolism: Key Regulators of Their Flux
Alejandro Gugliucci
Journal of Clinical Medicine.2023; 12(13): 4399. CrossRef - Remnant cholesterol, vascular risk, and prevention of atherosclerosis
Xavier Pintó, Marta Fanlo, Virginia Esteve, Jesús Millán
Clínica e Investigación en Arteriosclerosis (English Edition).2023; 35(4): 206. CrossRef - Antibiotics and Lipid-Modifying Agents: Potential Drug–Drug Interactions and Their Clinical Implications
Marios Spanakis, Danny Alon-Ellenbogen, Petros Ioannou, Nikolaos Spernovasilis
Pharmacy.2023; 11(4): 130. CrossRef - Advances in Treatment of Dyslipidemia
Jill Dybiec, Wiktoria Baran, Bartłomiej Dąbek, Piotr Fularski, Ewelina Młynarska, Ewa Radzioch, Jacek Rysz, Beata Franczyk
International Journal of Molecular Sciences.2023; 24(17): 13288. CrossRef - Peroxisome Proliferator-Activated Receptor α in Lipoprotein Metabolism and Atherosclerotic Cardiovascular Disease
Elena Valeria Fuior, Evangelia Zvintzou, Theodosios Filippatos, Katerina Giannatou, Victoria Mparnia, Maya Simionescu, Anca Violeta Gafencu, Kyriakos E. Kypreos
Biomedicines.2023; 11(10): 2696. CrossRef - Preparation, characterization and in vivo pharmacokinetic study of ginsenoside Rb1-PLGA nanoparticles
Lixin Du, Huiling Lu, Yifei Xiao, Zhihua Guo, Ya Li
Scientific Reports.2023;[Epub] CrossRef - Dysregulation of Cholesterol Homeostasis in Ovarian Cancer
Zahraa Qusairy, Anne Gangloff, Shuk On Annie Leung
Current Oncology.2023; 30(9): 8386. CrossRef - Riesgo residual. Conclusiones
Ángel Cequier, José Luis Zamorano
Revista Española de Cardiología Suplementos.2023; 23: 25. CrossRef - Causal effects of circulating lipids and lipid-lowering drugs on the risk of urinary stones: a Mendelian randomization study
Zilong Tan, Jing Hong, Aochuan Sun, Mengdi Ding, Jianwu Shen
Frontiers in Endocrinology.2023;[Epub] CrossRef - Bibliometric analysis of residual cardiovascular risk: trends and frontiers
Lin Wang, Sutong Wang, Chaoyuan Song, Yiding Yu, Yuehua Jiang, Yongcheng Wang, Xiao Li
Journal of Health, Population and Nutrition.2023;[Epub] CrossRef - Bempedoic acid: new evidence and recommendations on use
Kristina Paponja, Ivan Pećin, Željko Reiner, Maciej Banach
Current Opinion in Lipidology.2023;[Epub] CrossRef - Current Understanding on the Genetic Basis of Key Metabolic Disorders: A Review
Kenneth Francis Rodrigues, Wilson Thau Lym Yong, Md. Safiul Alam Bhuiyan, Shafiquzzaman Siddiquee, Muhammad Dawood Shah, Balu Alagar Venmathi Maran
Biology.2022; 11(9): 1308. CrossRef - Lipoprotein Lipase: Is It a Magic Target for the Treatment of Hypertriglyceridemia
Joon Ho Moon, Kyuho Kim, Sung Hee Choi
Endocrinology and Metabolism.2022; 37(4): 575. CrossRef
|
KDA
